UPMC Hillman Cancer Center is part of the UPMC family.

Mario Lemieux Center for Blood Cancers
Dr. Agha at the Mario Lemieux Center for Blood Cancer | UPMC Hillman
Mario Lemieux Center for Blood Cancers

Health Alert:

Starting Feb. 29, masking is optional but encouraged in UPMC medical facilities and most patient care settings.

Learn More

Myelodysplastic Syndromes (MDS) Clinical Trials at the Mario Lemieux Center for Blood Cancers

To learn more or speak with a trial coordinator, please call 412-864-6600.

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in subjects with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

Principal Investigator: Jing Hou, MD, PhD
Sponsor: AbbVie

View eligibility criteria and the full trial at ClinicalTrials.gov.

Evaluate the safety and efficacy of CC-486 and durvalumab in subjects with myelodysplastic syndromes who failed to achieve an objective response post iHMA treatment.

Principal Investigator: Robert Redner, MD
Sponsor: Celgene

View eligibility criteria and the full trial at ClinicalTrials.gov.